Reference : Bm-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in ...
Scientific congresses and symposiums : Poster
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/18447
Bm-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apoe–deficient mice
English
Cherdon, Céline mailto [Université de Liège - ULg > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique >]
Rolin, Stéphanie mailto [> >]
Hanson, Julien mailto [Université de Liège - ULg > Département de pharmacie > Chimie pharmaceutique >]
Drion, Pierre mailto [Université de Liège - ULg > Services généraux (Faculté de médecine vétérinaire) > Méth. expér. des anim. de labo et éthique en expér. animale >]
de Leval, Laurence mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques - Département des sciences biomédicales et précliniques >]
Defraigne, Jean-Olivier mailto [Université de Liège - ULg > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique >]
Dogné, Jean-Michel mailto [Université de Liège - ULg > Département de pharmacie > Département de pharmacie >]
22-Jun-2007
Yes
FROM CELL TO MAN TO SOCIETY - XIX World Congress of the ISHR
22-26 June 2007
International Society for Heart Research
Bologne
Italy
[en] BM-573 ; thromboxane ; apo E deficient mice ; atherosclerosis
[en] Atherosclerotic cardiovascular disease, according to World Health Organization, is the primary cause of heart disease and stroke. Atherosclerosis is a chronic vascular disease whose development is influenced by several mediators. Among them, the action of eicosanoïds such as thromboxane A2 and 8-iso-PGF2a have recently received a lot of attention. The aim of our study was the evaluation of benefits of original molecules, synthesised in our lab, targeting the thromboxane receptor (TP) in an apo E deficient mouse. We previously demonstrated in several in vitro and in vivo pharmacological experiments that our original sulfonylurea derivate, BM-573 was a potent combined inhibitor of the thromboxane synthase and antagonist of TP. Since TP is implied in atherosclerosis development, such antagonist could have a great therapeutic impact in atherogenesis.To test the efficacy of BM-573 in atherogenesis, the effect of 10 weeks of treatment with BM573 (10 mg/kg) on early aortic atherosclerotic lesions of apo E deficient mice was assessed. These mice were fed with chow diet, with spontaneous increase of total plasma cholesterol and triglycerides. In this experiment, while BM-573 did not affect body weight, it significantly decreased early atherogenesis lesions confirmed by macroscopic, microscopic and biochemical analysis. These results confirm that selective antagonism of TP receptor is effective in reducing atherosclerotic lesion in apo E deficient mice. Consequently, BM-573 could be a potential drug for prevention of atherosclerosis.
Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS
Researchers ; Professionals
http://hdl.handle.net/2268/18447

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
ISHR2007.pdfPublisher postprint93.5 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.